Cette page en français | Site map
Treatment
Treatment Phoneline 0808 800 6013 Mon-Wed 12-4pm
Avoiding & managing side effects – May 2008
bilirubin is a yellow-orange waste product from liver, hyper = increased; aemia = ‘in blood’.
Associated drugs: atazanavir (Reyataz); indinavir (Crixivan)
An increase in bilirubin (hyperbilirubinaemia) is a common side effect in 25-50% of people who use the protease inhibitors atazanavir or indinavir. Only a small percentage of people with increases in bilirubin develop jaundice.
The main symptoms of jaundice are a yellowing skin, or the white of the eyes being more yellow. This side effect in itself does not damage your body.
Bilirubin is an orange-yellow part of bile. Bile is the bright green fluid secreted by the liver to help digestion.
Bilirubin is mainly formed by the normal breakdown of haemoglobin. Haemoglobin carries oxygen in red blood cells.
Bilirubin passes through the liver. It is then excreted as bile through the intestines.
When this process is interrupted, excess bilirubin stains other body tissues yellow. Fatty tissues like skin, eye tissue and blood vessels are the most easily affected.
Increased levels of bilirubin are linked with a range of illnesses and conditions. This includes jaundice associated with hepatitis and cirrhosis, anaemia, Gilbert’s disease and sickle cell disease. Jaundice is common in babies. Very high levels in babies can cause permanent damage.
There are two types of bilirubin in the blood.
Routine blood tests for total bilirubin measure both unconjugated and conjugated bilirubin.
Increases in bilirubin with atazanavir are of unconjugated bilirubin. This occurs in around 30% of people using atazanavir. People who have lower levels of the enzymes responsible for converting bilirubin in the liver will be at a higher risk of increases in bilirubin from atazanavir.
Normal values may vary between different labs but are within the following ranges.
Jaundice becomes clinically detectable at levels above 40 mmol/l. You need good natural light to see this.
Treatment doesn’t usually need to be changed or the dose of atazanavir (or ritonavir) modified unless bilirubin levels become five times the upper limit of normal (5xULN). This is at around 60-70 mmol/l.
This yellowish skin can be unusual. When related to atazanavir though it is harmless and it is not causing damage to your body.
Only a few percent of people using atazanavir discontinue because of jaundice. Jaundice reverses within a couple of days of stopping atazanavir.
Just like many other protease inhibitors, atazanavir produces better results when used with ritonavir.
Because some people absorb higher levels of drugs anyway, some people may not need the additional boost from ritonavir.
High levels of bilirubin may be a marker of high levels of atazanavir. You can’t guess this though - you need to use TDM
In practice, people who get yellow skin or eyes when they use 300mg/day atazanavir boosted with 100mg ritonavir are often able to change to unboosted atazanavir (at 400mg/day). Note that the daily unboosted dose of atazanavir (2 x 200mg) is a higher dose than the boosted dose (2 x 150mg capsules).
It is very important that your doctor changes the formulation when not using ritonavir.
Many other drugs can also increase bilirubin levels. This includes anabolic steroids, some antibiotics, anti-malaria drugs, codeine, diuretics, morphine, oral contraceptives, rifampin and sulfonamides.
Drugs that can decrease bilirubin measurements include barbiturates, caffeine and penicillin.
This is the
web edition of the i-Base guide Avoiding & managing side effects.
This guide is available in UK clinics. You can order
free printed copies or download
a PDF version (564 Kb). There are also several translations. Decisions relating to your treatment should always be taken in consultation with your doctor. Information in this guide is intended to support those discussions
Top | i-Base guides | Home | Order & subscribe | Contact | Site map | Access